Late last year, a phase 3 clinical trial was published in the New England Journal of Medicine to wide acclaim. The 1,800-person, 18-month-long study centered around patients in the early stages of Alzheimer’s disease. It showed that a monoclonal antibody called lecanemab slowed declines in memory and thinking by 27%, a modest yet tangibly positive result. Despite lecanemab’s notable side effects, which included brain swelling in 12% of patients and brain bleeding in 17%, experts say it represents the most significant pharmaceutical advance against Alzheimer’s disease in decades.
Popular historian John Grundy publishes History of Northumberland chroniclelive.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from chroniclelive.co.uk Daily Mail and Mail on Sunday newspapers.